胃肠病学
胃腸病學
위장병학
CHINESE JOURNAL OF GASTROENTEROLOGY
2014年
12期
739-741
,共3页
抗体,抗中性白细胞胞质%氨基水杨酸类%结肠炎,溃疡性
抗體,抗中性白細胞胞質%氨基水楊痠類%結腸炎,潰瘍性
항체,항중성백세포포질%안기수양산류%결장염,궤양성
Antibodies,Antineutrophil Cytoplasmic%Aminosalicylic Acids%Colitis,Ulcerative
背景：血清核周型抗中性粒细胞胞质抗体（ pANCA ）在溃疡性结肠炎（ UC ）中的阳性率显著高于克罗恩病（ CD），对UC与CD的鉴别诊断具有重要意义。目的：探讨血清pANCA与氨基水杨酸（ ASA）制剂对UC治疗效果的关系。方法：采用回顾性研究方法，选取2007年1月至2013年12月在新疆维吾尔自治区人民医院确诊为轻、中度活动期UC并接受口服美沙拉秦治疗的患者70例，其中血清pANCA阳性和阴性患者各35例，比较两组临床疗效。结果：经口服美沙拉秦治疗4周，pANCA阳性组UC患者的临床缓解率和总有效率均明显高于pANCA阴性组，差异有统计学意义（临床缓解率：80.0%对54.3%，P﹤0.05；总有效率：94.3%对77.1%，P﹤0.05）。结论：美沙拉秦对血清pANCA阳性UC患者疗效显著。pANCA作为UC的特异性免疫学指标，可能对ASA制剂的疗效有一定预测价值。
揹景：血清覈週型抗中性粒細胞胞質抗體（ pANCA ）在潰瘍性結腸炎（ UC ）中的暘性率顯著高于剋囉恩病（ CD），對UC與CD的鑒彆診斷具有重要意義。目的：探討血清pANCA與氨基水楊痠（ ASA）製劑對UC治療效果的關繫。方法：採用迴顧性研究方法，選取2007年1月至2013年12月在新疆維吾爾自治區人民醫院確診為輕、中度活動期UC併接受口服美沙拉秦治療的患者70例，其中血清pANCA暘性和陰性患者各35例，比較兩組臨床療效。結果：經口服美沙拉秦治療4週，pANCA暘性組UC患者的臨床緩解率和總有效率均明顯高于pANCA陰性組，差異有統計學意義（臨床緩解率：80.0%對54.3%，P﹤0.05；總有效率：94.3%對77.1%，P﹤0.05）。結論：美沙拉秦對血清pANCA暘性UC患者療效顯著。pANCA作為UC的特異性免疫學指標，可能對ASA製劑的療效有一定預測價值。
배경：혈청핵주형항중성립세포포질항체（ pANCA ）재궤양성결장염（ UC ）중적양성솔현저고우극라은병（ CD），대UC여CD적감별진단구유중요의의。목적：탐토혈청pANCA여안기수양산（ ASA）제제대UC치료효과적관계。방법：채용회고성연구방법，선취2007년1월지2013년12월재신강유오이자치구인민의원학진위경、중도활동기UC병접수구복미사랍진치료적환자70례，기중혈청pANCA양성화음성환자각35례，비교량조림상료효。결과：경구복미사랍진치료4주，pANCA양성조UC환자적림상완해솔화총유효솔균명현고우pANCA음성조，차이유통계학의의（림상완해솔：80.0%대54.3%，P﹤0.05；총유효솔：94.3%대77.1%，P﹤0.05）。결론：미사랍진대혈청pANCA양성UC환자료효현저。pANCA작위UC적특이성면역학지표，가능대ASA제제적료효유일정예측개치。
Background:It has been demonstrated that serum perinuclear antineutrophil cytoplasmic antibody( pANCA)occurred significantly more often in ulcerative colitis( UC ) than in Crohn ’s disease( CD ),so it is of great importance for differential diagnosis of UC and CD. Aims:To study the correlation of serum pANCA with efficacy of aminosalicylic acids ( ASA)on UC. Methods:A retrospective study was conducted in 70 mild to moderate active UC patients admitted between Jan. 2007 and Dec. 2013 at People’s Hospital of Xinjiang Uygur Autonomous Region,all of them received oral mesalazine therapy,35 were positive and 35 were negative for serum pANCA. The efficacy was compared between the two groups. Results:After a four-week oral mesalazine therapy,the remission rate and overall efficacy were significantly higher in pANCA-positive group than in pANCA-negative group( remission rate:80. 0% us. 54. 3%,P﹤0. 05;overall efficacy:94. 3% us. 77. 1%,P﹤0. 05). Conclusions:Mesalazine is more effective in serum pANCA-positive UC patients. Being a specific immunological biomarker of UC,pANCA might be an indicator for predicting the therapeutic efficacy of ASA in UC patients.
